Novocure's electric field cancer therapy shows improved survival rates in pancreatic cancer trial.

Novocure's Tumor-Treating Fields (TTFields) therapy, which uses electric fields to target cancer cells, has shown promising results in a Phase 3 trial for advanced pancreatic cancer. When combined with chemotherapy, it improved median overall survival to 16.20 months, compared to 14.16 months for chemotherapy alone. The therapy was well-tolerated and Novocure plans to seek regulatory approval in the U.S., EU, Japan, and China.

December 02, 2024
11 Articles